

## ACUSPHERE INC. STOCKHOLDERS APPROVE REVERSE STOCK SPLIT AT SPECIAL MEETING OF STOCKHOLDERS

LEXINGTON, MASS., January 20, 2012 -- Acusphere, Inc. (ACUS.PK) today announced that its stockholders voted to approve the proposed 1-for-10 reverse stock split of the Company's common stock at its Special Meeting of Stockholders held today.

The Company intends to effect the reverse stock split immediately by filing an amendment to its certificate of incorporation, at which time every ten (10) shares of the Company's outstanding common stock will be automatically combined into one (1) outstanding share of common stock. This will reduce the number of outstanding shares of Acusphere common stock from approximately 51.0 million to 5.1 million. The number of authorized shares of Acusphere common stock will remain unchanged at 250.0 million, and the par value per share will remain unchanged at \$0.01. In lieu of issuing any fractional shares that would otherwise result from the reverse stock split, the Company will instead round up any such fractional share to the nearest whole number.

Sherri C. Oberg, President and Chief Executive Officer said, "We greatly appreciate the support and confidence of our shareholders in enabling us to take this important strategic step. We believe that by doing so, we are significantly enhancing our prospects to provide a tangible path forward for our lead product candidate, Imagify™ (Perflubutane Polymer Microspheres) for Injectable Suspension."

### **About Acusphere, Inc.**

Acusphere (ACUS.PK) is a specialty pharmaceutical company focused on the development and regulatory approval of its lead product candidate, Imagify™ (Perflubutane Polymer Microspheres) for Injectable Suspension. Imagify is a cardiovascular drug for the detection of coronary artery disease, the leading cause of death in the United States. Imagify and the Company's other product candidates were created using proprietary technology that enables Acusphere to control the porosity and size of nanoparticles and microspheres in a versatile manner that allows them to be customized to address the delivery needs of a variety of drugs. For more information about Acusphere visit the Company's web site ([www.acusphere.com](http://www.acusphere.com)).

### **Forward-looking Statements**

*The above press release contains forward-looking statements, including statements regarding the effectiveness and completion of the reverse stock split and the timing thereof. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors. The Company notes that effective as of March 3, 2009, pursuant to a Form 15 filing made with the SEC, it is not currently required to file periodic reports with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this press release or to reflect the occurrence of unanticipated events.*

For Information Contact:  
Kelley Wharff  
617-925-3444  
[ir@acusphere.com](mailto:ir@acusphere.com)